Cost-effectiveness of Controlling CPE (OPTIM-BHRe)

Cost-effectiveness of Strategies to Control the Spread of Carbapenemase-producing Enterobacteriaceae (CPE) in Hospitals

Spread of extensively drug-resistant bacteria (XDR) such as carbapenemase-producing Enterobacterales (CPE) is a major public health problem. Various prevention and control interventions are implemented to limit the transmission of XDR but they are expensive and often disrupt hospital organization. In this study, a mathematical model will be used to study the effectiveness and cost-effectiveness of control strategies to limit the spread of CPE in a general hospital ward. A case-control study will be conducted to estimate the excess length of stay and mortality attributable to CPE colonisation or infection.

Study Overview

• Status: Not yet recruiting
• Conditions: Carbapenemase-producing Enterobacteriaceae Infections

Detailed Description

Carbapenemase-producing Enterobacterales (CPE) are increasingly common in hospitals and represent a serious health problem. These multidrug-resistant organisms colonise the gastrointestinal tract after direct (person-to-person) or indirect (via contaminated surfaces) transmission and are a common cause of urinary tract infections, ventilator-associated pneumonia and bloodstream infections in healthcare settings. Treatment options for patients infected with CPE are limited leading to high mortality, increased length of hospital stay and hospital costs. The successful implementation of cost-effective infection control measures to prevent CPE spread and infections is key for infection control preventionists and hospital managers.

Recommendations to limit the transmission of CPE in healthcare facilities are based on the early detection of asymptomatic carriers, implementation of contact precautions and isolation in single room. In practice, strategies combining various interventions are employed according to the risk assessment and available resources: 1) universal or targeted rectal screening on admission, 2) standard precautions (SP), applied to all patients regardless of their infectious status, 3) contact precautions (CP) for identified carriers or infected patients, 4) isolation in a single room, 5) environmental cleaning, 6) rectal screening of contact patients, i.e. those whose care was provided by the same team as the CPE patient, and/or 7) isolation of carriers in a dedicated area with dedicated nursing staff (DNS), thereafter designated as cohorting.

However, these control measures pose challenges such as the high cost of patient's screening and cohorting, requirement for single room isolation or staff shortage for implementing precautions. Moreover, the effectiveness and cost-effectiveness of various CPE control strategies is under-documented.

OBJECTIVES:

Primary:

To evaluate the cost-effectiveness of different strategies combining screening and contact precaution measures to control the spread of CPE in a general medicine ward (GW) using a mathematical model.

Secondary:

• To assess the impact of CPE colonisation/ infection on patient's outcome (mortality, length of stay)
• To analyse the resources used to manage CPE cases
• To analyse the care pathway of a CPE case and study whether carrying the CPE represents the opportunity loss for the patient,

METHODS AND TOOLS:

A dynamic, stochastic model simulates the transmission of CPE by the hands of healthcare workers (HCWs) and the environment in a hypothetical GW. Input parameters are based on data from APHP hospitals and from the literature.

12 strategies are compared to the baseline (no control) and combined different prevention and control interventions: targeted or universal screening at admission (TS or US), contact precautions (CP), isolation in a single room, dedicated nursing staff (DNS) for carriers and weekly screening of contact patients (WS). Time horizon is one year.

A hospital perspective is adopted to estimate costs, which included laboratory costs, single room, contact precautions, staff time, i.e. infection control nurse and/or nurses for cohorting, and lost bed-days due to prolonged hospital stay of identified carriers.

A case-control study will be conducted to assess the impact of CPE colonization / infection on patient's outcomes. Cases will be the patients newly identified as CPE colonized or infected during the first semester 2016 in the APHP hospital network, i.e. around 450 cases. In the case of hospital CPE outbreak, index and secondary cases will be included. Cases will be followed until discharge from the hospital setting, including rehabilitation or home care. Since all discharges in France, either from public or private HCFs, are registered in the single national hospital discharge database PMSI (HDD), it is possible to link all hospital stays and retrieve the entire hospital course.

Controls will be selected in the national HDD on a 1:1 ratio, based on the following matching criteria: absence of known colonization with CPE, age, gender, hospital stay in the same unit as the corresponding case during the 1st semester 2016, same DRG and duration of hospital stays at least as long at the time to colonization in the case.

The following information will be collected in cases and controls:

• demographic data, country of born (and if so date of entry in France),
• Charlson comorbidity score, McCabe score, activity of daily living (ADL) score at discharge from the index hospital stay,
• main and secondary DRG in the HDD system,
• socioeconomic status, estimated by the address of living (IRIS score), type of registration in the national insurance security,
• origin at hospital admission, whether the case is an index or secondary CPE colonized/infected,
• whether the case was only colonized or infected, type of Enterobacteriaceae carrying the resistance gene, and type of resistance gene
• control measures implemented for controlling the episode: contact precautions, reinforced personnel, dedicated personnel, interruption of admission and transfers
• activity of the unit of first admission: number of bed, yearly number of admissions and hospital days A cost-effectiveness analysis will be undertaken to find the most favourable control strategies from the model simulations. Sensitivity analysis will identify the factors that have the greatest impact on the results.

• Study Type: Observational
• Enrollment (Anticipated): 1800

Contacts and Locations

• Study Contact: Name: Jean Christophe Pr Lucet, Professor; Phone Number: +33 140 256 194; Email: jean-christophe.lucet@aphp.fr
• Study Contact Backup: Name: Isabelle Pr Durand-Zaleski, Professor; Phone Number: +33 140 274 143; Email: isabelle.durand-zaleski@aphp.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

The study is based on numerical simulations and data collected from APHP hospitals. We will model the transmission of CPEs and the interventions implemented against these bacteria in a 25-bed non-intensive care unit. Transmission between patients is considered to occur through caregivers, nurses and orderlies.

We will conduct a case-control study in patients colonized or infected with CEP, hospitalized at APHP hospitals between January and June 2019.

Description

Inclusion Criteria:

• patients infected with emerging highly resistant bacteria at acute care hospital.

Exclusion Criteria:

• patients infected while hospitalized in intensive care unit.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Retrospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
cases; Patients colonized or infected with CPE
controls; Patients not colonized or infected with CPE

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ICER- the ratio of the difference in costs to difference in health benefits	The incremental cost-effectiveness ratios (ICER) calculated as the extra annual cost of one strategy relative to another divided by CPE cases avoided by that strategy relative to the other strategy	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of CPE acquisitions	Number of CPE acquisitions observed for each strategy simulated in the model	6 months after the end of the data collection
Costs of strategies	Description: costs associated with each strategy (e.g. laboratory costs, cost of single room, contact precautions, staff time)	6 months after the end of the data collection
Number of days when hospital admissions interrupted	Number of days when the presence of EPC in a ward leads to the interruption of new admissions	6 months after the end of the data collection
Number of days when hospital transfers interrupted	Description: Number of days when the presence of EPC in a ward leads to the interruption of transfers	6 months after the end of the data collection
frequency of employment of dedicated staff	% of situations where dedicated staff were employed for the management of CPE cases	6 months after the end of the data collection
length of hospital stay of patients	length of hospital stay for cases (CPE infected or colonised patients) and controls	6 months after the end of the data collection
risk of death	risk of in-hospital death for cases (CPE infected or colonised patients) and controls	6 months after the end of the data collection

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris

Study record dates

Study Major Dates

• Study Start (Anticipated): March 1, 2022
• Primary Completion (Anticipated): September 1, 2022
• Study Completion (Anticipated): September 1, 2023

Study Registration Dates

• First Submitted: November 25, 2021
• First Submitted That Met QC Criteria: February 28, 2022
• First Posted (Actual): March 9, 2022

Study Record Updates

• Last Update Posted (Actual): March 9, 2022
• Last Update Submitted That Met QC Criteria: February 28, 2022
• Last Verified: July 1, 2021

More Information

Terms related to this study

• Keywords: CPE spread; CPE infections; CPE deaths
• Additional Relevant MeSH Terms: Infections; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Enterobacteriaceae Infections
• Other Study ID Numbers: OPTIM BHRe

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No